- Purification method of rosuvastatin calcium key intermediate
-
The invention provides a purification method of a rosuvastatin calcium intermediate. The rosuvastatin calcium intermediate has a structure of a compound (4). The purification method comprises following steps: adding an alcohol solvent and water into a crude product containing the compound (4), then adding an ether solvent, cooling, and crystallizing to obtain the compound (4). The structure of thecompound (4) is represented in the description. The provided purification method has the advantages of simple operation, high yield, and good selectivity, can obtain high purity rosuvastatin calciumkey intermediate, which is used to prepare high quality rosuvastatin calcium, and improves the drug quality.
- -
-
Paragraph 0053-0055; 0062; 0063
(2019/05/08)
-
- NOVEL METHOD FOR PREPARING ROSUVASTATIN, INTERMEDIATE COMPOUNDS USEFUL FOR PREPARING SAME, AND METHOD FOR PREPARING SAME
-
The present invention relates to novel intermediate compounds used in preparing Rosuvastatin or the pharmaceutically acceptable salts thereof, to a method for preparing same, and to a method for preparing Rosuvastatin or the pharmaceutically acceptable salts thereof from the intermediates. The preparation method of the present invention has the effect of providing Rosuvastatin hemi-calcium salts with an excellent yield rate.
- -
-
-
- NOVEL METHOD FOR PREPARING ROSUVASTATIN, INTERMEDIATE COMPOUNDS USEFUL FOR PREPARING SAME, AND METHOD FOR PREPARING SAME
-
The present invention relates to novel intermediate compounds used in preparing Rosuvastatin or the pharmaceutically acceptable salts thereof, to a method for preparing same, and to a method for preparing Rosuvastatin or the pharmaceutically acceptable salts thereof from the intermediates. The preparation method of the present invention has the effect of providing Rosuvastatin hemi-calcium salts with an excellent yield rate.
- -
-
-
- Chemical Process
-
A process for formation of a compound of formula (I) or a pharmaceutically acceptable salt thereof, (A chemical formula should be inserted here—please see paper copy enclosed herewith) I via a Heck reaction is described. Intermediates useful in the process and processes for making said intermediates are also described.
- -
-
Page/Page column 16-17
(2008/12/08)
-
- Process for the preparation of pyrimidine derivatives
-
An improved process for the preparation of pyrimidine derivatives is provided comprising reacting a Wittig reagent of the general formula wherein R is an alkyl of from 1 to 10 carbon atoms, aryl or arylalkyl, R1 is a substituted or unsubstituted hydrocarbon group, R2 and R3 are the same or different and are hydrogen or a substituted or unsubstituted hydrocarbon group; Z is sulfur, oxygen, sulfonyl, or imino which may be substituted by formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, amino substituted by sulfonyl or alkylsulfonyl, and sulfonyl substituted by alkyl, amino or alkylamino and X is a halogen; with an aldehyde of the general formula wherein R4 is hydrogen, a lower alkyl or a cation capable of forming a non-toxic pharmaceutically acceptable salt and each R5 are the same or different and are hydrogen or a hydrolyzable protecting group, or each R5, together with the oxygen atom to which each is bonded, form a hydrolyzable cyclic protecting group, or each R5 is bonded to the same substituent which is bonded to each oxygen atom to form a hydrolyzable protecting group; in the presence of a base.
- -
-
Page/Page column 6-8; 10-11
(2010/02/11)
-
- Crystalline salts of 7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3r,5s)-3,5-dihydroxyhept-6-enoic acid
-
The invention relates to crystalline salts of the compound (E)-7-[4-(4-fluorophenyl)-6-iso-propyl-2-[methyl(methyl-sulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid of formula (I),as well as processes for their manufacture, pharmaceutical compositions containing them, and their uses.
- -
-
-